What is Inogen's cash & equivalents?

Inogen (INGN) reported cash & equivalents of $93.11M in Q1 2026.

How has Inogen's cash & equivalents changed year-over-year?

Inogen's cash & equivalents decreased by 21.7% year-over-year, from $118.89M to $93.11M.

What is the long-term trend for Inogen's cash & equivalents?

Over 5 years (2020 to 2025), Inogen's cash & equivalents has grown at a -13.3% compound annual growth rate (CAGR), from $211.96M to $103.73M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Inogen INGN Cash & Equivalents

Cash & Equivalents at other companies

ResMedRMD

$1.66B+78.0%

AdaptHealthAHCO

$47.96M-10.6%

Viemed Healthcare, Inc.VMD

$9.76M-3.9%

SavaraSVRA

$38.79M+98.4%

Tactile Systems TechnologyTCMD

$74.99M-10.3%

iRhythm Holdings, Inc. IRTC

$248.5M-35.2%

Other financials

Income statement

See full

Revenue$85.1M+3.4%

Gross profit$44.9M+1.7%

Operating income-$9.3M-21.9%

Net income-$8.3M-34.8%

EPS (diluted)-$0.30-20.0%

Balance sheet

See full

Total debt$16.9M-11.9%

Total equity$182.9M-7.6%

Total assets$285.9M-7.3%

Cash flow

See full

Operating cash flow-$6.7M+60.2%

CapEx$210.0K-28.1%

Free cash flow-$6.9M+59.6%

Valuation

See full

Market cap$174.63M-9.7%

Enterprise value$98.45M-9.5%

P/S0.5×-0.1×

Profitability

See full

Gross margin52.8%-2.6pp

Operating margin-9.1%-0.8pp

Net margin-7.1%-0.8pp

FCF margin0.4%—

Returns & leverage

See full

Return on equity-13.1%-0.9pp

Debt / equity0.1×0.0×

Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inogen's cash & equivalents?: Inogen (INGN) reported cash & equivalents of $93.11M in Q1 2026.
How has Inogen's cash & equivalents changed year-over-year?: Inogen's cash & equivalents decreased by 21.7% year-over-year, from $118.89M to $93.11M.
What is the long-term trend for Inogen's cash & equivalents?: Over 5 years (2020 to 2025), Inogen's cash & equivalents has grown at a -13.3% compound annual growth rate (CAGR), from $211.96M to $103.73M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.